Lataa...
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions w...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2660292/ https://ncbi.nlm.nih.gov/pubmed/19265512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-6-25 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|